Omvoh Disease Interactions
There are 3 disease interactions with Omvoh (mirikizumab).
Mirikizumab-mrkz (applies to Omvoh) active infection
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Mirikizumab may increase the risk of infection. Patients should be evaluated for active infection before and during treatment with mirikizumab, and administration should be avoided if infection is detected.
Mirikizumab-mrkz (applies to Omvoh) hepatic impairment and cirrhosis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Mirikizumab can cause increased levels of liver enzymes and bilirubin. The effect of moderate to severe hepatic impairment on the pharmacokinetics of mirikizumab has not been evaluated. Other treatment options should be considered in patients with evidence of liver cirrhosis.
Mirikizumab-mrkz (applies to Omvoh) Tuberculosis (TB)
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, Tuberculosis -- Latent
Patients treated with mirikizumab may be at increased risk for tuberculosis. Patients should be evaluated for TB before treatment with mirikizumab and therapy should be avoided in patients with active TB. Anti-TB therapy should be considered for patients with a history of latent or active TB.
Switch to professional interaction data
Omvoh drug interactions
There are 212 drug interactions with Omvoh (mirikizumab).
More about Omvoh (mirikizumab)
- Omvoh consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.